Cynmark24:
I understand your uneasiness but would like to point you to a reassuring example on how our R/S could likely play out. Take a long look at Arena Pharma (ARNA). I've followed this company for decades as it's located in my San Diego backyard.
Over the years they've destroyed shareholder value and dreams a number of times, a veritable wasteland of products. They reinvented themselves a couple of years ago and were trading on NASDAQ at $1.30 last May. They announced a 1/10 R/S on June 14th that went into effect just three days later on June 19th at roughly $1.45. Their 317,000,000 shares became 31.7 million and price was $14.80 - Here's where it got fun;
On July 10th they announced positive top line data for Phase II 'Ralinepal" for pulmonary arterial hypertension. Price jumped to $24.00 and the next day they announced the pricing of a public offering of 6,250,000 shares at $24.00 to raise $150 million- They need it as they lose approximately $100 million per year. The price dropped to $20.00 but from there continued to climb slowly.
Yesterday they reported positive Phase II results on OASIS trial for "Etrasimod" for ulcerative colitis. Price jumped to $44 and settled at $40. - Another proposed public offering was announced today- I think CYDY is a leaner, meaner better company and product line than ARNA - If management plays it right I see no reason we can't see the same or superior PPS rise as Arena - From $14.00 to $44.00 in the months after the RS and raise boatloads of cash on our terms- GLTA
News 
Market Data 
Discover 
